News

Karyopharm Therapeutics Inc. announced new regulatory designations for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for…
Read More...

ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address…
Read More...

Sorrento Therapeutics, Inc. announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic…
Read More...

Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company…
Read More...

Gilead Sciences and the European Commission signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury (remdesivir) for…
Read More...

Nabriva Therapeutics plc announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the…
Read More...

Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients announced the U.S. Food and…
Read More...

AbbVie announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who…
Read More...

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and…
Read More...

Amylyx Pharmaceuticals, Inc. announced a two-year sponsored research agreement with Sunnybrook Research Institute (SRI) to expedite the identification of novel drug candidates that…
Read More...

Moderna, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a…
Read More...

Everest Medicines announced that our partner Calliditas Therapeutics AB has been granted conditional marketing authorization for Kinpeygo (developed under the name NEFECON) by the…
Read More...

Endo International plc announced that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. for the development, registration, supply,…
Read More...

NeoImmuneTech, Inc. (NIT) announced that the U.S. Food and Drug Administration (FDA) has granted NT-I7 (efineptakin alfa) (rhIL-7-hyFc) Orphan Drug Designation for the treatment of…
Read More...

SK Biopharmaceuticals, Co., Ltd., announced that it has entered into a licensing agreement for Eurofarma, a Brazilian pharmaceutical company with business in over 20 countries, to…
Read More...

Zymergen Inc. announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five…
Read More...

Today, Health Canada authorized the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. This is the first COVID-19 vaccine authorized in Canada for use…
Read More...

Codexis, Inc. announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate…
Read More...

Labcorp announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury. The new Neurofilament Light Chain…
Read More...

Orion Corporation and MSD announced a global development and commercialisation agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1…
Read More...